Although statins have demonstrated potential in enhancing efferocytosis and reducing neutrophil-driven inflammation (as evidenced by reductions in C-reactive protein and IL-6) in clinical analyses, these benefits have not yet translated into clear clinical outcomes for COPD patients [107]. The gene discussed is IL6; the disease is chronic obstructive pulmonary disease.